Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.

Period	Debt/Equity
2018-12-31	0.43
2019-12-31	0.56
2020-12-31	0.07
2021-12-31	0.08
2022-12-31	0.18
2023-12-31	0.22
2024-12-31	0.28

	A	B	C	D
1	Symbol	Price	Change	Volume
2	COGT	$35.21	+0.00%	1.97M
3
4
5

Cogent Biosciences Inc. (COGT) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Cogent Biosciences Inc. Data in Excel

More COGT Financial Data